Stocks / NYSE / CryoLife, Inc.

CryoLife, Inc.

Our Opinion

CryoLife, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.

Supporting Evidence:

CryoLife, Inc. Files Application With FDA for SynerGraft: World’s First Tissue-Engineered Heart Valve

The company announced in the following press release that, “The valve repopulation process has been proven successful in advanced animal studies that showed that the heart valve’s collagen matrix was repopulated with newcells and tissue architecture from the valve recipient.”

Company Description

CryoLife, Inc. is a medical devices company. It engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. The company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, HeRO Graft, and ProCol. The Preservation Services segment offers external services revenues from the preservation of cardiac and vascular tissues. CryoLife was founded by Steven G. Anderson on January 19, 1984 and is headquartered in Kennesaw, GA. [Source: MarketWatch]

Company Website: http://www.cryolife.com